Matthew Schlumbrecht, MD
Gynecologic Oncology · Miami, FLNPI 1427251529
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,850 of the $8,674 with a category attached, or 90.5%. GSK accounts for 94.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $4,056 and has fallen 55.6% since, to $1,801 in 2025.
Across 23 payments — averaging $377.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- AbbVie$268
- Seagen Inc.$100
- Eisai Inc.$85
- Immunogen, Inc.$30
- AstraZeneca$24
Across 103 payments — averaging $161,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$16.3M
- Pfizer$124K
- AstraZeneca$78K
- Clovis Oncology, Inc.$67K
- Genmab U.S., Inc.$42K
- Daiichi Sankyo Inc.$34K
What the payments were for
- Consulting fees$7,85091%
- Food & beverage$7248%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $8,167 |
| AbbVie | 3 | $268 |
| Seagen Inc. | 1 | $100 |
| Eisai Inc. | 3 | $85 |
| Immunogen, Inc. | 1 | $30 |
| AstraZeneca | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,674 in reported general payments places this provider in the 70th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 23 | $400 |
| Gabapentin | 18 | $288 |
| Ondansetron Hcl | 23 | $278 |
| Letrozole | 20 | $277 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $148 |
| Ibuprofen | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Miami
- Ricardo EstapeMiami$457K
- Troy GatcliffeMiami$172K
- John DiazMiami$87K
- Jean-Marie StephanMiami$40K
- Eric SchroederMiami$10K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.